Project Grant R03CA301367
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $318K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
- Federal Grant Award Summary The University of Oklahoma Health Sciences Center received a $424,480 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 11, 2025, through August 31, 2029. This award supports the Promoting Lead Academic Participating Sites (LAPS) Studies Accrual and Lung Cancer Screening in Oklahoma initiative, which addresses Oklahoma's elevated lung cancer mortality rate (46.5 per 100,000...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center a Project Grant totaling $361,695 under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2029. This NCI Research Specialist (Clinician Scientist) Award supports the principal investigator's efforts to improve cancer screening and clinical trial enrollment through multiple integrated initiatives. The award enables protected...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center a Project Grant of $376,490 under the Cancer Treatment Research program (CFDA 93.395) beginning July 1, 2025 and concluding June 30, 2027. This award supports research and development of a novel therapeutic combination strategy targeting cervical cancer through the integration of a C-MYC inhibitor (MYCI975) with SHETA2, an investigational heat shock protein inhibitor...
- Summary of Federal Grant Award Northwestern University, through its Sponsored Research Division, received a $1.45 million Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective September 1, 2025, through August 31, 2030. This research project investigates the role of adverse social-biological interactions in acute myeloid leukemia (AML) disparities, examining how sociodemographic characteristics and neighborhood...
- Federal Grant Award Summary The University of Oklahoma Health Sciences Center received a $211,628 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective August 1, 2025, through July 31, 2030. The Cancer Undergraduate Research Experience (CURE) in Oklahoma initiative provides high-quality research training in cancer-related fields to undergraduate students under the mentorship of 53 participating faculty mentors. Participants engage in...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded September 11, 2025, with completion targeted for August 31, 2030. The award supports fundamental research to identify and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs) as a therapeutic target for acute myeloid leukemia (AML) patients. The research...
- Federal Project Grant Summary Children's Hospital Los Angeles received an $8.47 million Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 10, 2025, with completion targeted for August 31, 2029. The grant funds a patient navigation intervention designed to improve transition success for multiply disadvantaged young adult survivors of childhood cancer (CCS). The research addresses a critical gap in...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $3,032,826 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective September 1, 2025, with a completion date of August 31, 2030. This award supports the FUSONC Program Project, which investigates fusion oncoproteins (FOPs)—abnormal proteins arising from gene translocations that drive approximately 17% of all cancers and are particularly...
- Federal Project Grant Summary The National Cancer Institute awarded $528,902 to The University of Texas Southwestern Medical Center on September 12, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a five-year research project examining genomic correlates of outcome in pleuropulmonary blastoma (PPB). The project focuses on understanding how different DICER1 gene variants affect clinical prognosis, microRNA production, and tumor behavior in pediatric lung...
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...